AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
OCALA, Fla., July 03, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced the next CEO Corner segment has been published on the Company's website. For the CEO Corner segment, AIM Chief Executive Officer Thomas Equels provided an update on the Phase 1b/2 "DURIPANC" study of Ampligen and AstraZeneca's Imfinzi as a combination therapy for late-stage pancreatic cancer. The Company also provided a business update, including that as a result of recent financings, AIM recently had stockholders' equity of $6.9 million.
佛羅里達州奧卡拉，2024年7月3日——AIM ImmunoTech Inc.（紐約證券交易所美國股票代碼：AIM）（“AIM” 或 “公司”）今天宣佈，下一期首席執行官專欄已在公司網站上發佈。在首席執行官專欄中，AIM首席執行官托馬斯·埃克爾斯提供了對Ampligen和阿斯利康的Imfinzi作爲晚期胰腺癌聯合療法的1b/2期 “DURIPANC” 研究的最新情況。該公司還提供了最新業務情況，包括由於最近的融資，AIM最近的股東權益爲690萬美元。
The CEO Corner segment is now available here.
首席執行官專區現已在此處提供。
About AIM ImmunoTech Inc.
關於 AIM ImmunoTech Inc
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's lead product is a first-in-class investigational drug called Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
AIM ImmunoTech Inc. 是一家免疫製藥公司，專注於研究和開發治療多種類型的癌症、免疫疾病和病毒性疾病（包括 COVID-19）的療法。該公司的主導產品是一種名爲Ampligen（rintatolimod）的同類首創研究藥物，它是一種dsRNA和高選擇性TLR3激動劑免疫調節劑，在全球重要的癌症、病毒性疾病和免疫系統疾病的臨床試驗中具有廣譜活性。
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
欲了解更多信息，請訪問aimimmuno.com並通過X、LinkedIn和Facebook與公司聯繫。
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
AIM@jtcir.com
投資者聯繫人：
JTC Team, LLC
珍妮·托馬斯
(833) 475-8247
AIM@jtcir.com
